The costs and benefits of psychedelics on cognition and mood
Neuron January 20, 2023 Ceyda Sayalı, Frederick S. Barrett 40 citations
No Summary
Ceyda Sayalı
Johns Hopkins University
3 papers in the library · 49 citations · publishing 2023-2026
Papers
Learned Helplessness As a Potential Transdiagnostic Therapeutic Mechanism of Classic Psychedelics
Psychedelic Medicine June 1, 2023 Praachi Tiwari, Andrea Berghella, Ceyda Sayalı et al. 9 citations
Classic psychedelics may treat mood and substance use disorders by reversing learned helplessness, a well-studied phenomenon across mammals. The neural circuits underlying resilience to learned helplessness, including the dorsal raphe nucleus, overlap with those activated by psychedelics. Preclinical data show psychedelics improve performance in rodent behavioral despair tasks, supporting this hypothesis. The learned helplessness paradigm offers a robust model for investigating psychedelic mechanisms across behavioral, neurobiological, and clinical levels, potentially explaining transdiagnostic therapeutic effects.
Acute Cardiovascular Effects of Psilocybin: A Pooled Analysis of 14 Studies with Safety Recommendations
medRxiv Preprint Server April 28, 2026 Sandeep M. Nayak, Nathan D. Sepeda, Matthew Nielsen Dick et al. preprint
Psilocybin is being studied as a treatment for psychiatric and neurologic conditions, but there is limited comprehensive data on its cardiovascular safety. Current clinical trials typically exclude people with blood pressure of 140/90 mmHg or higher, a cutoff set conservatively without strong empirical evidence.